Erasca, Inc.
- ERAS
- NASDAQ
- Biotechnology
- Oncology Biotech
- RAS/MAPK Targeted Therapies
$14.62
Today +7.34%Quote Oct 20, 2026, 08:00 PM UTC
−7.79%over the last month
Max drawdown −16.5%From 1-month high −15.0%3 months −29.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Erasca
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
103
Founded
2018
Market value
$5.11B
Quote Oct 20
Floor
$14.22
2.7% below price
Resistance
$15.18
3.8% above price
Price vs analyst targets
11 analysts
Lowest target
$16.00Highest target
$30.00
$16.00Highest target
$30.00
- Price $14.62
- Average target $22.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 54% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ERASPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free